Caricamento...
The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M
[Image: see text] The winners of the Malcolm Campbell Memorial Prize for 2017 discuss the structure-guided discovery of Osimertinib and the difficulties associated with discovering a new drug.
Salvato in:
| Pubblicato in: | Medchemcomm |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Royal Society of Chemistry
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6072417/ https://ncbi.nlm.nih.gov/pubmed/30108799 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1039/c7md90012k |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|